Background/Aims: Hypoxia modulation of transforming growth factor (TGF)-β-induced signaling during myofibroblast transformation is dependent on the specific cell type. The purpose of this study was to explore the effects of hypoxia on myofibroblast transformation of TGF-β1-induced cardiomyocyte H9c2 cells. Methods: H9c2 cells were cultured for intermittent hypoxia treatment and TGF-β1 treatment. α-Smooth muscle actin (α-SMA) expression was examined by western blotting and immunofluorescence after treatment. To further explore the possible mechanism for this effect, the effects of hypoxia on three early TGF-β-dependent signaling pathways, i.e. the Smad2/3, RhoA and mitogen-activated protein kinase (MAPK) pathways, were screened by western blotting. Results: Intermittent hypoxia induced TGF-β1 expression, but had no effect on α-SMA expression. Exogenous TGF-β1 alone upregulated α-SMA expression in H9c2 cells in a concentration-and time-dependent manner. α-SMA expression declined with the duration of hypoxia after intermittent hypoxia and exogenous TGF-β1 cotreatment. Phospho-JNK and phospho-p38 levels were not significantly altered after TGF-β1 and hypoxia treatment. However, levels of phospho-ERK increased after TGF-β1 treatment and continued to increase after hypoxia co-treatment. The activation of phospho-Smad2/3 and phospho-RhoA induced by TGFβ1 was significantly reduced after hypoxia co-treatment. Conclusion: Hypoxia can inhibit TGF-β1-induced H9c2 myofibroblast transformation, based on inhibition of α-SMA expression by suppressing signaling downstream of TGF-β1, Smad2/3 and RhoA. It suggested that TGF-β-mediated cardiomyocyte transformation is not involved in hypoxia-mediated fibrosis.
Introduction
Cardiac fibrosis is a common consequence of heart disease, such as myocardial infarction, hypertrophy, hypertension and ischemia-reperfusion [1] [2] [3] . Hypoxia is an important factor in initiating cardiac fibrosis, which can modulate transdifferentiation from fibroblasts into myofibroblasts, proliferation and extracellular matrix composition (ECM) [4] [5] [6] . Fibroblasts, and related myofibroblasts, are the principle producers of ECM and contribute significantly to fibrosis in the heart [7, 8] . Myofibroblasts, which are distinguished by the expression of α-smooth muscle actin (α-SMA), are generated from a variety of sources, including resident mesenchymal cells, and epithelial and endothelial cells in processes termed epithelial/ endothelial-mesenchymal transition (EMT/EndMT). In addition, myofibroblasts are also derived from circulating fibroblast-like cells, called fibrocytes, which themselves are derived from bone-marrow stem cells [9] .
Transforming growth factor (TGF)-β plays a key role in myofibroblast transformation, as well as EMT [10] [11] [12] . TGF-β activates a heteromeric complex of type I and type II serine/ threonine kinase receptors to induce phosphorylation of Smad2/3 transcription factors [13] . Phospho-Smad2/3 (p-Smad2/3) combines with commonly-expressed Smad4 and enters the nucleus to recruit the coactivator, CBP (CREB binding protein)/p300, to regulate downstream genes and alter ECM expression [14] [15] [16] . TGF-β can also activate mitogen-activated protein kinase (MAPK) signaling [17] and Ras homolog gene family, member A (RhoA) pathways [18] either independently or as modulators of Smads.
Zhang, et al. reported that hypoxia increases TGF-β expression and concomitant downstream effectors, Smads, in human umbilical vein endothelial cells [19] . However, Chen et al. found that both TGF-β1 and hypoxia increased ECM expression in placental fibroblasts, but TGF-β production was not increased under hypoxia, suggesting that ECM production can be stimulated independently by hypoxia and TGF-β1 [20] . More interestingly, Xing et al. found that hypoxia reduces TGF-β1-induced corneal keratocyte myofibroblast transformation and α-SMA expression, possibly by reducing the early activation of RhoA [10] . These studies suggest that the profibrotic or anti-fibrotic effects of hypoxia could be dependent on the specific cell type.
Cardiac myocytes, which comprise almost 75% percent of the heart [21] , are assumed be the victims of cardiac fibrosis. However, our previous oligonucleotide array-based transcription factor assay (OATFA) screen found that hypoxia enhances E47 (transcription factor-3，TCF-3) and hypoxia-inducible factor (HIF) activity in primary cardiac myocytes of neonatal rats. Several studies concerning the molecular regulation of EMT suggest that E2A transcription factors E12 and E47, which result from alternative splicing, play a critical role in driving alterations in gene expression profile during EMT [22] [23] [24] . The promoters of two key genes involved in the EMT process, E-cadherin and α-SMA, contain a number of E-box motifs that enable the binding of E2A transcription factors [22, 25] . Because cardiac myocytes may be induced to undergo myofibroblast transformation, and hypoxia/reoxygenation can increase the expression of fibrosis-related proteins, including fibronectin, collagen I and III in cardiomyocyte H9c2 cells [26] , in light of the possibility that the interplay between hypoxia and TGF-β is cell type-specific, we explore the interplay between hypoxia and TGF-β1 on myofibroblast transformation in cardiomyocyte H9c2 cells.
Materials and Methods

Cell culture
The cardiac myocyte H9c2 cells (ATCC, USA) were inoculated into 60 mm dishes (at approximately 10 5 cells per dish) containing 5 ml of Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, and cultured under 95% air and 5% CO 2 at 37°C. Culture medium was changed every 2 days. 
TGF-β1 and hypoxia treatment
For TGF-β1 treatment, recombinant TGF-β1 (Cell signaling Technology, USA) was added into the culture medium and cells were incubated for various times. For hypoxia treatment, cells were incubated in a hypoxia workstation (Baker Ruskin, UK) equilibrated with 1% oxygen/5% CO 2 -balance nitrogen. In consideration of cell viability under long-term hypoxia exposure, cells were exposed to hypoxia for 1-h durations every 6 h, over a 24-h period, concurrently with or without TGF-β1.
Western blot
Cells were lysed with cell lysis buffer containing a protease inhibitor cocktail, and total protein was measured using a BCA kit (Thermo Fisher). Extracts were denatured by boiling for 5 min in sample buffer. Equal amounts of total protein (50 μg) were subjected to 8-10% SDS-PAGE, and then were electrophoretically transferred onto nitrocellulose membranes. Nonspecific binding was blocked by incubation of membranes with TBST containing 10% skim milk for 1 h at room temperature. The blot was incubated with antibodies against α-SMA (Sigma); TGF-β1, Smad2/3, p-Smad2/3, p-ERK, p-JNK, p-p38, RhoA (Cell signaling technology); and p-RhoA (Abcam) overnight at 4°C, then washed 3 times with TBST and incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (1:1000) for 1 h at room temperature. Immunoreactive bands were visualized with chemiluminescence luminol reagent (Thermo Fisher). β-Actin (1:1000, Abcam) was used to confirm equal loading of samples. Individual blots were scanned and the desired proteins quantified using densitometry.
Immunofluorescence staining Cultured H9c2 were fixed with 4% paraformaldehyde for 15 min at room temperature, and permeabilized in 0.1% Triton X-100 with phosphate-buffered saline (PBS). Cells were then blocked with 5% BSA for 1 h, stained with mouse α-SMA antibody (1:100) in blocking medium overnight at RT, washed thrice with PBS, and incubated with goat anti-mouse IgG Alexa Fluor 488 (1:100) for 2 h. Cells were washed four times with PBS, then stained with Hoechst 33250 for10 min, washed with PBS, then photographed under a fluorescence microscope.
Statistical analysis
All data are expressed as mean±S.E.M. and analyzed with SPSS 17.0 statistical software (SPSS Inc.). The significance of the differences was determined using one-way ANOVA followed by an L.S.D. test. P < 0.05 was considered statistically significant.
Results
The expression of TGF-β1 and α-SMA after hypoxia treatment As shown in Fig. 1A , very low expression of TGF-β1 was detected in control H9c2 cells, but the production of TGF-β1 increased more than 2-fold at 13 and 19 h after intermittent hypoxia (p < 0.05). Therefore, hypoxia induces the expression of TGF-β1. Strangely, the expression of α-SMA did not significantly change after hypoxia treatment for various times. Since α-SMA, a myofibroblast marker, is representative of the contractile 
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Effect of TGF-β1 addition on expression of α-SMA
Following stimulation of H9c2 cells with different concentrations (1, 5, 10, 20, 30 ng/ml) of TGF-β1 for 24 h, the expression of α-SMA increased with increasing concentration of TGF-β1 ( Fig. 2A) , with a statistically significant difference achieved at 5 ng/ml TGF-β1 compared with the control (p < 0.05). Then we observed the expression of α-SMA at various times (6, 12, 
Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry 24, 32, 48 h) following addition of 5 ng/ml TGF-β1 (Fig. 2B) . The expression of α-SMA increased with the time, and peaked nearly 3-fold at about 24 h (p < 0.05). These results show that the effects of TGF-β1 addition are different from that of endogenous TGF-β1 induced by hypoxia.
Effect of hypoxia and exogenous TGF-β1 cotreatment on expression of α-SMA
We examined the expression of α-SMA after intermittent hypoxia treatment for varying times concurrent with TGF-β1 (5 ng/ ml) treatment for 24 h. As shown in Fig. 3A , exogenous TGF-β1 alone upregulated α-SMA expression. However, increasing duration of hypoxia treatment increasingly diminished exogenous TGF-β1-induced α-SMA expression, reduced to the control group level at about 13 h after intermittent hypoxia. To confirm the result, we examined immunofluorescence intensity of α-SMA in groups. Addition of TGF-β1 alone enhanced the fluorescence intensity of α-SMA. When combined with hypoxia treatment, the fluorescence intensity of α-SMA was increasingly reduced with increases of hypoxia duration in 24 h (Fig. 3B) . The immunofluorescence results were consistent with that of western blotting. This suggests that hypoxia suppresses TGF-β1 signaling.
The effect hypoxia on the expression of TGF-β-induced p-Smad2/3, p-RhoA and MAPKs
As shown in Fig. 4A , compared with the control, expression of p-Smad2/3 in the TGF-β1-treated cells was increased about 3-fold (p < 0.05). However, the expression of p-Smad2/3 in TGF-β1+hypoxia group was increasingly decreased with increasing hypoxia time compared with cells treated with TGF-β1 alone (p < 0.05). A decrease in expression of p-RhoA was similar to the hypoxia-mediated decrease in p-Smad2/3 (Fig. 4B) . TGF-β1 treatment induced about 5-fold up-regulation of p-ERK. However, co-treatment with hypoxia for 1 h decreased about half of the expression of p-ERK compared with TGF-β1-treated cells (p < 0.05), then p-ERK levels gradually increased with increasing hypoxia exposure (Fig. 4C) . The expression of p-JNK and p-p38 was unaffected by TGF-β1 treatment and hypoxia co-treatment (Fig. 4C) .
Discussion
In this study, we demonstrate that hypoxia inhibits TGF-β1-induced H9c2 cell transformation into myofibroblasts., potentially by suppressing the activation of Smad2/3 and RhoA, a downstream signaling pathway activated by TGF-β1, consequently reducing the expression of α-SMA. Hypoxia is thought to be one of the most significant causes of tissue fibrosis. Hypoxia causes elevated expression of TGF-β1 in the myocardium [28, 29] and stimulates cardiac fibroblast transdifferentiation to myofibroblasts [30] . However, our studies show that in H9c2 cells, although hypoxia induces the expression of TGF-β1, hypoxia has no effect on α-SMA expression. Then we examined the effects of exogenous TGF-β1 alone or with hypoxia co-treatment. Exogenous TGF-β1 induces α-SMA expression in a concentration-and time-dependent manner. However, this TGF-β1-mediated induction was diminished by hypoxia, indicating that hypoxia reduces TGF-β1-induced α-SMA expression in H9c2 cells. So, we speculated that hypoxia may suppress the downstream signal pathway of TGF-β1 to obstruct the α-SMA expression at the same time. It suggested that TGF-β-mediated cardiomyocyte transformation is not involved in hypoxia-mediated fibrosis.
To explore the possible mechanism by which hypoxia inhibits the ability of TGF-β1 to promote myofibroblast transformation, we observed early events in the signaling pathways induced by TGF-β. It has been reported that Smads are required for TGF-β-induced α-SMA expression in fibroblasts [31, 32] . We found that the expression of p-Smad2/3 increases significantly after exogenous TGF-β1 stimulation, but gradually decreases with time after hypoxia. This suggests that Smad2/3 might be involved in hypoxia inhibition of TGF-β1-induced α-SMA in H9c2 cells. Smads require coactivators CBP1 and p300 for transcriptional activity [33] . One possible mechanism for inhibition of TGF-β-induced myofibroblast transformation may be hypoxia-induced HIF, which also requires the same coactivators [34] , to bring about competition for CBP/p300 with Smads, thereby altering the TGF-β response.
RhoA is a member of the Ras superfamily of GTP-binding proteins, which is activated by phosphorylation, then subsequently activates downstream effector Rho-kinases (ROCKs). TGF-β can rapidly activate RhoA-dependent signaling pathways to induce EMT [18] . It has been reported that RhoA/ROCK involvement in remodeling of the myocardial matrix in diabetic rats may be associated with activation of the TGF-β/Smad pathway [35] . The changes in p-RhoA expression are similar to our observation of Smads under hypoxia and TGF-β1 co-treatment. This suggests that the RhoA pathway might also be involved in hypoxia inhibition of TGF-β1-induced α-SMA in H9c2 cells.
Members of the MAPK family can be activated by TGF-β in a Smad-independent manner and phosphorylate Smad3 [17] . The MAPK family is well-known for signaling in TGF-β1-induced fibrosis [36, 37] . Liu et al. have demonstrated that reduction of ERK1/2 phosphorylation and Smad-mediated recruitment of transcriptional coactivators inhibits the profibrotic effects of TGF-β in cardiac fibroblasts [38] . We find that the expression of p-JNK and p-p38 in H9c2 cells is unaffected by hypoxia after TGF-β1 and hypoxia cotreatment, which suggests that JNK and p38 are not likely to be involved in the TGF-β1-induced myofibroblast transformation in H9c2 cells. Expression of p-ERK is elevated after TGF-β1 treatment, consistent with previous findings that TGF-β1 induces lung fibroblastto-myofibroblast conversion via ERK1/2 activation [36] . Interestingly, co-treatment with hypoxia and TGF-β1 increases the expression of p-ERK with hypoxia time, same as the effect of TGF-β1, but less than TGF-β1 treatment alone at 1 h after hypoxia co-treatment. The pathophysiological effects of p-ERK change in H9c2 cells is unknown and needs to be further investigated, but whatever the effects of p-ERK change are, hypoxia-mediated inhibition of myofibroblast differentiation does not occur through inhibition of ERK phosphorylation. Our results suggest that cardiac myocytes may utilize different signal transduction pathways from fibroblasts for hypoxia-mediated myofibroblast differentiation.
Although the H9c2 cell line was originally derived from embryonic BD1X rat heart tissue, and does not fully represent myocardiocytes, our findings suggest that hypoxia could inhibit TGF-β-induced signaling during myofibroblast transformation in cardiac myocytes. The profibrotic or anti-fibrotic effects of hypoxia are probably dependent on the specific cell type. Hypoxia can induce TGF-β1 upregulation in cardiac myocytes, but cardiomyocyte TGF-β1 may exert paracrine actions to stimulate cardiac fibroblast-to-myofibroblast conversion, but have no effect to cardiomyocytes themselves in regard to α-SMA expression. Further experiments are needed to confirm the findings in cardiac myocytes, and to explore the precise mechanisms by which cardiac myocytes are blocked from myofibroblast transformation.
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